Pharmaron Beijing Co., Ltd.
300759
Clasificación en acciones
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Precio por acción
$5.58
Capitalización bursátil
$8.24B
Cambio (1 día)
-3.77%
Cambio (1 año)
28.36%
País
CN
Comercio Pharmaron Beijing Co., Ltd. (300759)
Categoría
Healthcare
Ganancias de Pharmaron Beijing Co., Ltd. (300759)
Ganancias en Jun 2026 TTM: $303.40M
Secondo gli ultimi rapporti finanziari di Pharmaron Beijing Co., Ltd., gli utili attuali della società sono $303.40M. Nel 2024, la società ha registrato un utile di $286.51M, un aumento con respecto a agli utili del 2023, che erano di $259.64M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Pharmaron Beijing Co., Ltd. desde 2014 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $303.40M | 10.98% |
| 2025 | $273.38M | -4.58% |
| 2024 | $286.51M | 10.35% |
| 2023 | $259.64M | 7.48% |
| 2022 | $241.58M | -19.65% |
| 2021 | $300.66M | 48.87% |
| 2020 | $201.96M | 122.33% |
| 2019 | $90.84M | 59.17% |
| 2018 | $57.07M | 33.32% |
| 2017 | $42.81M | 38.55% |
| 2016 | $30.90M | 129.26% |
| 2015 | $13.48M | 188.75% |
| 2014 | $4.67M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 1,638.58% |
US
|
|
| $-3.09B | -1,117.46% |
US
|
|
| $-4.02B | -1,423.72% |
AU
|
|
| $3.01B | 890.67% |
BE
|
|
| $1.95B | 542.93% |
NL
|
